Jonathan Milner

DefiniGEN Ltd. provides human cell products to the drug discovery sector. Its services include iPSC Differentiation, Gene Editing, CRISPR Modeling and Patient Derived Models. The firm products include Hepatocytes, Intestinal and Pancreatic. The company was founded in April 2012 by Candy Hsin-Hua Cho, Nicolas R. F. Hannan, Roger A. Pedersen and Tamir Rashid and is headquartered in Cambridge, the United Kingdom.

GeoSpock Ltd. provides data software products. It offers illumin, extrapol and cogn8 products. The company was founded by Steven Marsh and Darrin Mathew Disley in 2013 and is headquartered in Cambridge, the United Kingdom.

Horizon Discovery Group Ltd. is a cell engineering company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research & Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research & Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in July 2005 and is headquartered in Cambridge, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Repositive Ltd. engages in developing a platform for facilitating access to and sharing of human genomic data. The company platform includes features for discovery of available data, making users data visible to the research community, managing users data sources, and initiating data collaborations. Its platform also integrates methods for secure data sharing and a mechanism for secure privacy-preserving data access. The company was founded by Fiona Nielsen and Adrian Alexa in August 2014 and is headquartered in Cambridge, the United Kingdom.

Cambridge Allergy Ltd. operates as a biopharmaceutical company which manufactures medicines for food allergies. The company was founded by Sherden Timmins, Andrew Clark, and Pamela Ewan on December 7, 2015 and is headquartered in Cambridge, the United Kingdom.

Avocet 66 Ltd. is a British financial intermediary company founded in 2017.

Peregrine 66 Ltd. is a British investment services company founded in 2017. The private company is based in London, UK. The company provides investment services.

Suntail 66 Ltd. provides financial intermediary services. The private company is based in London, UK.

Start Codon Ltd (Start Codon) is a venture capital firm founded in 2018 by Jason Mellad and Marek Tyl. The firm is headquartered in London, United Kingdom.

Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom.